Mass Balance and Metabolic Profiling of Avacopan, a Selective C5a Receptor 1 Antagonist, in Healthy Humans
Study results provide a definitive assessment of the absorption, elimination, and nature of metabolism of avacopan in humans.
Authors
- Pirow Bekker (ORCID: https://orcid.org/0000-0003-0219-7188)
- Rajneet K. Oberoi (ORCID: https://orcid.org/0000-0001-9522-9948)
- Yang Song (ORCID: https://orcid.org/0000-0002-7558-9804)
- Ezra Tai
- Andrew M. K. Pennell
- Penglie Zhang (ORCID: https://orcid.org/0000-0001-6941-4357)
- Antoni Krasinski
- Sara Wills (ORCID: https://orcid.org/0000-0002-2436-9393)
- Ruiping Zhao
- Xiaoli Liu (ORCID: https://orcid.org/0000-0003-0986-6487)
- Yibin Zeng (ORCID: https://orcid.org/0000-0003-3597-5142)
- Shichang Miao
Institutions
- Amgen (United States) (US)
- LabCorp (United States) (US)
- ChemoCentryx (United States) (US)
Publication Details
- Journal
- Current Drug Metabolism
- Published
- 2025-10-15
- DOI
- https://doi.org/10.2174/0113892002370460251006055528
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.00